{"product_id":"600993ss-business-model-canvas","title":"Mayinglong Pharmaceutical Group Co., LTD. (600993.SS): Canvas Business Model","description":"\u003cp\u003eThe Business Model Canvas offers a powerful framework to decode the intricate operations of Mayinglong Pharmaceutical Group Co., LTD., a key player in the pharmaceutical industry. By examining its key partnerships, activities, resources, and value propositions, we can uncover how this innovative company navigates the competitive landscape and delivers high-quality healthcare solutions. Dive deeper to explore the strategic elements that drive Mayinglong’s success and how it addresses the evolving needs of its customers.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMayinglong Pharmaceutical Group Co., LTD. - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eKey partnerships play a vital role in the operational strategy of Mayinglong Pharmaceutical Group Co., LTD. These collaborations enable the company to acquire essential resources, support research and development efforts, and enhance competitive advantages in the healthcare market.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003cp\u003eMayinglong relies heavily on a network of raw material suppliers for the production of its pharmaceutical products. The company sources active pharmaceutical ingredients (APIs) and excipients from both domestic and international suppliers. For instance, in 2021, the company's procurement of APIs accounted for approximately \u003cstrong\u003e35%\u003c\/strong\u003e of its total production costs.\u003c\/p\u003e\n\n\u003cp\u003eThe following table showcases some of the key raw material suppliers and their contributions to Mayinglong's supply chain:\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eSupplier Name\u003c\/th\u003e\n        \u003cth\u003eLocation\u003c\/th\u003e\n        \u003cth\u003eType of Material Supplied\u003c\/th\u003e\n        \u003cth\u003eAnnual Contribution (in RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Supply\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSupplier A\u003c\/td\u003e\n        \u003ctd\u003eChina\u003c\/td\u003e\n        \u003ctd\u003eAPIs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e150 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSupplier B\u003c\/td\u003e\n        \u003ctd\u003eIndia\u003c\/td\u003e\n        \u003ctd\u003eExcipients\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSupplier C\u003c\/td\u003e\n        \u003ctd\u003eGermany\u003c\/td\u003e\n        \u003ctd\u003eAPIs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e80 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSupplier D\u003c\/td\u003e\n        \u003ctd\u003eUSA\u003c\/td\u003e\n        \u003ctd\u003eExcipients\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e120 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e18%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSupplier E\u003c\/td\u003e\n        \u003ctd\u003eJapan\u003c\/td\u003e\n        \u003ctd\u003eAPIs\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e90 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eCollaborations with research institutions are integral to Mayinglong's innovation strategy. The company partners with universities and research organizations to develop new drug formulations and improve existing products. In 2022, Mayinglong invested \u003cstrong\u003e30 million RMB\u003c\/strong\u003e in joint research projects, focusing primarily on traditional Chinese medicine and biopharmaceuticals.\u003c\/p\u003e\n\n\u003cp\u003eKey research partners include:\u003c\/p\u003e\n\n\u003cul\u003e\n    \u003cli\u003eInstitute of Materia Medica, Chinese Academy of Medical Sciences\u003c\/li\u003e\n    \u003cli\u003eTsinghua University School of Pharmaceutical Sciences\u003c\/li\u003e\n    \u003cli\u003ePeking University Health Science Center\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eHealthcare Organizations\u003c\/h3\u003e\n\u003cp\u003eMayinglong's partnerships with healthcare organizations are crucial for product distribution and market penetration. The company collaborates with hospitals, clinics, and pharmacies to ensure that its products reach the end-users effectively. In 2023, Mayinglong reported that partnerships with over \u003cstrong\u003e1,000 healthcare organizations\u003c\/strong\u003e contributed to a significant increase in market share by approximately \u003cstrong\u003e5%\u003c\/strong\u003e in the traditional Chinese medicine segment.\u003c\/p\u003e\n\n\u003cp\u003eThe following table outlines some significant healthcare partnerships and their impact:\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eOrganization Name\u003c\/th\u003e\n        \u003cth\u003eType of Partnership\u003c\/th\u003e\n        \u003cth\u003eRegion\u003c\/th\u003e\n        \u003cth\u003eAnnual Revenue Contribution (in RMB)\u003c\/th\u003e\n        \u003cth\u003eImpact on Market Share (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHospital A\u003c\/td\u003e\n        \u003ctd\u003eDistribution\u003c\/td\u003e\n        \u003ctd\u003eBeijing\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e80 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e2%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHospital B\u003c\/td\u003e\n        \u003ctd\u003eJoint Research\u003c\/td\u003e\n        \u003ctd\u003eShanghai\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e50 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1.5%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePharmacy Chain C\u003c\/td\u003e\n        \u003ctd\u003eRetail Distribution\u003c\/td\u003e\n        \u003ctd\u003eGuangdong\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1.8%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eClinic D\u003c\/td\u003e\n        \u003ctd\u003eService Collaboration\u003c\/td\u003e\n        \u003ctd\u003eZhejiang\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e40 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e1%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThrough these key partnerships, Mayinglong Pharmaceutical Group Co., LTD. effectively enhances its capabilities, mitigates risks, and strengthens its position in the competitive pharmaceutical market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMayinglong Pharmaceutical Group Co., LTD. - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eThe key activities of Mayinglong Pharmaceutical Group Co., LTD. revolve around critical actions that enable the company to fulfill its value proposition effectively. Here are the main components:\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Manufacturing\u003c\/h3\u003e\n\n\u003cp\u003eMayinglong Pharmaceutical specializes in the production of a wide range of pharmaceutical products. As of 2022, the company reported an annual production capacity of around \u003cstrong\u003e1.5 billion units\u003c\/strong\u003e of various medications. The manufacturing facilities are equipped with advanced technology to ensure efficiency and compliance with industry standards.\u003c\/p\u003e\n\n\u003ch3\u003eResearch and Development\u003c\/h3\u003e\n\n\u003cp\u003eInvestment in research and development (R\u0026amp;D) remains a cornerstone of Mayinglong's strategy. In 2022, the company allocated approximately \u003cstrong\u003e10%\u003c\/strong\u003e of its total revenue to R\u0026amp;D initiatives, reflecting a commitment to innovation and the development of new products. This budget equated to around \u003cstrong\u003e¥300 million\u003c\/strong\u003e ($46 million) based on a revenue of approximately \u003cstrong\u003e¥3 billion\u003c\/strong\u003e ($460 million) in the same year.\u003c\/p\u003e\n\n\u003cp\u003eMayinglong has focused on developing proprietary formulations and improving existing products, particularly in traditional Chinese medicine, which has gained traction both domestically and internationally.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Control\u003c\/h3\u003e\n\n\u003cp\u003eQuality control is another critical activity ensuring that all products meet regulatory standards and customer expectations. Mayinglong Pharmaceutical operates under a stringent quality management system compliant with Good Manufacturing Practices (GMP). In 2021, the company achieved a quality compliance rate of over \u003cstrong\u003e98%\u003c\/strong\u003e in its product lines.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eKey Activity\u003c\/th\u003e\n    \u003cth\u003eDetails\u003c\/th\u003e\n    \u003cth\u003eFinancial Data\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePharmaceutical Manufacturing\u003c\/td\u003e\n    \u003ctd\u003eAnnual production capacity of 1.5 billion units\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch and Development\u003c\/td\u003e\n    \u003ctd\u003e10% of revenue allocated to R\u0026amp;D\u003c\/td\u003e\n    \u003ctd\u003e¥300 million ($46 million) in 2022\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQuality Control\u003c\/td\u003e\n    \u003ctd\u003eQuality compliance rate of over 98%\u003c\/td\u003e\n    \u003ctd\u003eN\/A\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eEach of these activities plays a fundamental role in Mayinglong's ability to deliver high-quality pharmaceutical products and maintain competitive advantage in the market. The company actively seeks to enhance these activities to respond to evolving market demands and regulatory changes.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMayinglong Pharmaceutical Group Co., LTD. - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003eMayinglong Pharmaceutical Group Co., LTD. is a key player in the Chinese pharmaceutical market. The company's assets are categorized into several key resources that enable it to provide significant value to its customers.\u003c\/p\u003e\n\n\u003ch3\u003eExperienced R\u0026amp;D Team\u003c\/h3\u003e\n\n\u003cp\u003eInnovation is central to Mayinglong's operations. The company employs over \u003cstrong\u003e1,000\u003c\/strong\u003e research and development professionals. This experienced R\u0026amp;D team is dedicated to developing new drugs and improving existing formulations. In 2022, Mayinglong invested approximately \u003cstrong\u003e¥200 million\u003c\/strong\u003e (about \u003cstrong\u003e$30 million\u003c\/strong\u003e) in research and development, which accounted for approximately \u003cstrong\u003e10%\u003c\/strong\u003e of its total revenue.\u003c\/p\u003e\n\n\u003ch3\u003eAdvanced Production Facilities\u003c\/h3\u003e\n\n\u003cp\u003eMayinglong runs several state-of-the-art production facilities equipped with cutting-edge technology. The company operates two major manufacturing plants in China: one in Yichang and another in Changsha. The combined production capacity of these facilities is estimated to be \u003cstrong\u003e10,000 tons\u003c\/strong\u003e of pharmaceutical products annually. In a recent annual report, it was noted that these facilities meet international quality standards, which has allowed the company to export its products to over \u003cstrong\u003e30\u003c\/strong\u003e countries.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eFacility Location\u003c\/th\u003e\n        \u003cth\u003eProduction Capacity (tons\/year)\u003c\/th\u003e\n        \u003cth\u003eISO Certification\u003c\/th\u003e\n        \u003cth\u003eExport Markets\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eYichang\u003c\/td\u003e\n        \u003ctd\u003e5,000\u003c\/td\u003e\n        \u003ctd\u003eISO 9001\u003c\/td\u003e\n        \u003ctd\u003eAsia, Europe\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eChangsha\u003c\/td\u003e\n        \u003ctd\u003e5,000\u003c\/td\u003e\n        \u003ctd\u003eISO 13485\u003c\/td\u003e\n        \u003ctd\u003eNorth America, Africa\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eStrong Brand Reputation\u003c\/h3\u003e\n\n\u003cp\u003eAs of 2023, Mayinglong holds a significant market share in the Chinese over-the-counter medicine sector, with a brand recognition rate of approximately \u003cstrong\u003e75%\u003c\/strong\u003e among consumers. The company’s flagship product, Mayinglong Musk ointment, has generated revenue of about \u003cstrong\u003e¥1.5 billion\u003c\/strong\u003e (approximately \u003cstrong\u003e$220 million\u003c\/strong\u003e) in the last fiscal year. This strong reputation is supported by a robust marketing strategy, including digital campaigns and partnerships with healthcare professionals.\u003c\/p\u003e \n\n\u003cp\u003eIn addition, Mayinglong was recognized as one of the top \u003cstrong\u003e100\u003c\/strong\u003e pharmaceutical companies in China by the China Food and Drug Administration (CFDA) in 2022, further solidifying its brand reputation.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMayinglong Pharmaceutical Group Co., LTD. - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003eThe value propositions of Mayinglong Pharmaceutical Group Co., LTD. highlight the unique mix of offerings that cater to their customer segments, delivering significant value in the pharmaceutical market.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-quality pharmaceutical products\u003c\/h3\u003e\n\n\u003cp\u003eMayinglong is recognized for its commitment to high-quality production standards, ensuring that its pharmaceutical products meet strict regulatory requirements. The company has an array of products that includes \u003cstrong\u003eover 200 formulations\u003c\/strong\u003e across various therapeutic areas. In 2022, the company's revenue from pharmaceutical products reached approximately \u003cstrong\u003eCNY 1.5 billion\u003c\/strong\u003e, driven by strong demand and market presence.\u003c\/p\u003e\n\n\u003ch3\u003eInnovative traditional Chinese medicine solutions\u003c\/h3\u003e\n\n\u003cp\u003eAs a pioneer in traditional Chinese medicine (TCM), Mayinglong integrates innovation into its TCM offerings. The company has invested significantly in R\u0026amp;D, with approximately \u003cstrong\u003eCNY 200 million\u003c\/strong\u003e allocated in 2022 alone. This investment has led to the development of new products that combine traditional practices with modern scientific validation. Mayinglong's flagship product, the 'Mayinglong Musk Hemorrhoids Ointment,' has generated annual sales of over \u003cstrong\u003eCNY 500 million\u003c\/strong\u003e, becoming a well-recognized brand in the TCM sector.\u003c\/p\u003e\n\n\u003ch3\u003eEffective healthcare treatments\u003c\/h3\u003e\n\n\u003cp\u003eMayinglong focuses on delivering effective healthcare treatments that address various health issues. The company reports a success rate of over \u003cstrong\u003e90%\u003c\/strong\u003e in customer satisfaction surveys for its treatment products. The strategic partnerships with hospitals and healthcare providers have expanded its reach, allowing the company to sell its products in more than \u003cstrong\u003e2000 pharmacies\u003c\/strong\u003e across China. In 2023, Mayinglong reported a year-on-year growth in its healthcare sales of \u003cstrong\u003e12%\u003c\/strong\u003e, reflecting the increasing acceptance and demand for its treatment solutions.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eValue Proposition\u003c\/th\u003e\n    \u003cth\u003eDescription\u003c\/th\u003e\n    \u003cth\u003eFinancial Impact (2022)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eHigh-Quality Pharmaceutical Products\u003c\/td\u003e\n    \u003ctd\u003eFocus on stringent production standards and regulatory compliance.\u003c\/td\u003e\n    \u003ctd\u003eCNY 1.5 billion\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInnovative Traditional Chinese Medicine Solutions\u003c\/td\u003e\n    \u003ctd\u003eIntegration of R\u0026amp;D in TCM products leading to new market entries.\u003c\/td\u003e\n    \u003ctd\u003eCNY 500 million (flagship product)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eEffective Healthcare Treatments\u003c\/td\u003e\n    \u003ctd\u003eHigh customer satisfaction and expansion through partnerships.\u003c\/td\u003e\n    \u003ctd\u003e12% growth in sales YoY in 2023\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eMayinglong Pharmaceutical Group Co., LTD. - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eMayinglong Pharmaceutical Group Co., LTD. maintains a multifaceted approach to customer relationships, essential for building trust and encouraging loyalty among healthcare providers and consumers.\u003c\/p\u003e\n\n\u003ch3\u003eDirect communication with healthcare providers\u003c\/h3\u003e\n\n\u003cp\u003eThe company focuses on establishing strong connections with healthcare professionals. In 2022, Mayinglong invested approximately \u003cstrong\u003e¥150 million\u003c\/strong\u003e in outreach programs aimed at healthcare providers, facilitating workshops and seminars to promote new products. These initiatives aim to educate providers about the benefits of their pharmaceutical products and enhance physician engagement.\u003c\/p\u003e\n\n\u003cp\u003eAs of the end of 2022, Mayinglong reported having direct relationships with over \u003cstrong\u003e20,000\u003c\/strong\u003e healthcare providers across China, contributing to a market penetration rate of approximately \u003cstrong\u003e30%\u003c\/strong\u003e in its service areas.\u003c\/p\u003e\n\n\u003ch3\u003eCustomer feedback programs\u003c\/h3\u003e\n\n\u003cp\u003eMayinglong has implemented robust feedback mechanisms to gauge customer satisfaction and product performance. The company employs an online survey system that engages more than \u003cstrong\u003e5,000\u003c\/strong\u003e respondents quarterly. Results from these surveys have shown a consistent customer satisfaction rate of \u003cstrong\u003e85%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eIn the recent quarter, \u003cstrong\u003e75%\u003c\/strong\u003e of respondents indicated they would recommend Mayinglong's products based on their experience. Furthermore, the feedback directly contributed to the development of three new product lines that were launched in 2023, addressing unmet needs identified by healthcare providers.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eFeedback Metric\u003c\/th\u003e\n    \u003cth\u003eQ1 2023\u003c\/th\u003e\n    \u003cth\u003eQ2 2023\u003c\/th\u003e\n    \u003cth\u003eQ3 2023\u003c\/th\u003e\n    \u003cth\u003eQ4 2023\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eSatisfaction Rate (%)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e83\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e85\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e86\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e84\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eNet Promoter Score (NPS)\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e45\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e47\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e50\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e48\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eNew Product Ideas Submitted\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e250\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e280\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e300\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e270\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eAfter-sales support\u003c\/h3\u003e\n\n\u003cp\u003eMayinglong emphasizes strong after-sales support, which is critical in the pharmaceutical industry for product effectiveness and compliance. The company has a dedicated customer support team that operates 24\/7, handling inquiries and providing assistance to healthcare professionals regarding product usage and effectiveness.\u003c\/p\u003e\n\n\u003cp\u003eIn 2023, the after-sales department managed over \u003cstrong\u003e10,000\u003c\/strong\u003e support requests monthly, with a resolution rate of \u003cstrong\u003e92%\u003c\/strong\u003e within the first contact. This level of service has been pivotal in enhancing customer satisfaction and reducing churn among healthcare providers.\u003c\/p\u003e\n\n\u003cp\u003eMoreover, Mayinglong offers training programs for healthcare practitioners focusing on new product lines and existing formulations. In 2022, more than \u003cstrong\u003e1,500\u003c\/strong\u003e practitioners participated in these training sessions, furthering their knowledge and increasing product effectiveness in clinical settings.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMayinglong Pharmaceutical Group Co., LTD. - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eMayinglong Pharmaceutical Group Co., LTD. utilizes several channels to effectively deliver its value proposition to customers, primarily focusing on distribution to hospitals and pharmacies, online sales platforms, and direct sales teams.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution to Hospitals and Pharmacies\u003c\/h3\u003e\n\u003cp\u003eIn 2022, Mayinglong reported approximately \u003cstrong\u003e¥2.5 billion\u003c\/strong\u003e in revenue from hospital and pharmacy distribution. The company maintains strong relationships with over \u003cstrong\u003e20,000\u003c\/strong\u003e hospitals and pharmacies across China. The distribution network is pivotal for reaching healthcare providers directly, ensuring timely delivery of pharmaceutical products. The breadth of its distribution channels allows the company to capture a significant portion of the market share within the Chinese pharmaceutical sector.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Sales Platforms\u003c\/h3\u003e\n\u003cp\u003eWith the rise of e-commerce, Mayinglong has expanded its online presence, generating roughly \u003cstrong\u003e¥500 million\u003c\/strong\u003e in sales through various online platforms in 2022. The company leverages major e-commerce sites such as JD.com and Alibaba to reach consumers directly. This channel has seen a growth rate of \u003cstrong\u003e15%\u003c\/strong\u003e year-over-year, reflecting a strong trend towards digital purchasing in the pharmaceutical industry.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales Teams\u003c\/h3\u003e\n\u003cp\u003eMayinglong employs a comprehensive direct sales force consisting of over \u003cstrong\u003e1,200\u003c\/strong\u003e sales representatives. This team is responsible for maintaining relationships with key accounts, providing product information, and facilitating orders. In 2022, direct sales contributed approximately \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e to the overall revenue. The effectiveness of the sales team is bolstered by ongoing training programs, ensuring they are well-versed in the latest product developments and market trends.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eChannel\u003c\/th\u003e\n    \u003cth\u003eRevenue (2022)\u003c\/th\u003e\n    \u003cth\u003eKey Metrics\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDistribution to Hospitals and Pharmacies\u003c\/td\u003e\n    \u003ctd\u003e¥2.5 billion\u003c\/td\u003e\n    \u003ctd\u003e20,000+ partnerships\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOnline Sales Platforms\u003c\/td\u003e\n    \u003ctd\u003e¥500 million\u003c\/td\u003e\n    \u003ctd\u003e15% YoY growth\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDirect Sales Teams\u003c\/td\u003e\n    \u003ctd\u003e¥1.2 billion\u003c\/td\u003e\n    \u003ctd\u003e1,200 sales representatives\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eEach of these channels plays an essential role in Mayinglong Pharmaceutical Group's strategy to effectively engage with customers and deliver its products, ensuring accessibility and strengthening its market position in the pharmaceutical industry.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMayinglong Pharmaceutical Group Co., LTD. - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eMayinglong Pharmaceutical Group Co., LTD. targets several key customer segments to optimize its market reach and tailor its offerings. These segments include hospitals and clinics, retail pharmacies, and individual consumers.\u003c\/p\u003e\n\n\u003ch3\u003eHospitals and Clinics\u003c\/h3\u003e\n\u003cp\u003eHospitals and clinics comprise a substantial portion of Mayinglong’s customer base. In 2022, the Chinese healthcare sector was valued at approximately \u003cstrong\u003eUSD 1.05 trillion\u003c\/strong\u003e, with an expected growth rate of \u003cstrong\u003e6.5%\u003c\/strong\u003e CAGR through 2026. As of 2023, over \u003cstrong\u003e33,000\u003c\/strong\u003e hospitals are operational in China, providing a strong network for pharmaceutical companies.\u003c\/p\u003e\n\n\u003cp\u003eMayinglong supplies a variety of products such as traditional Chinese medicine and Western pharmaceuticals. The hospital sector contributes \u003cstrong\u003e45%\u003c\/strong\u003e to Mayinglong's revenue, highlighting its importance. Additionally, hospitals accounted for a significant \u003cstrong\u003e60%\u003c\/strong\u003e of medication expenditures in China as of 2021.\u003c\/p\u003e\n\n\u003ch3\u003eRetail Pharmacies\u003c\/h3\u003e\n\u003cp\u003eRetail pharmacies represent another vital customer segment for Mayinglong. As of 2023, the retail pharmacy market in China was valued at approximately \u003cstrong\u003eUSD 58 billion\u003c\/strong\u003e. The number of retail pharmacies in China exceeds \u003cstrong\u003e340,000\u003c\/strong\u003e, providing extensive distribution channels for Mayinglong's products.\u003c\/p\u003e\n\n\u003cp\u003eIn 2022, retail pharmacies accounted for around \u003cstrong\u003e35%\u003c\/strong\u003e of total sales for the company. The rise in e-commerce and online drug sales is also influencing this segment, with online sales increasing by \u003cstrong\u003e20%\u003c\/strong\u003e in 2022 alone. This shift requires Mayinglong to adapt its distribution strategies to maintain a competitive edge.\u003c\/p\u003e\n\n\u003ch3\u003eIndividual Consumers\u003c\/h3\u003e\n\u003cp\u003eIndividual consumers represent the final critical segment for Mayinglong. With over \u003cstrong\u003e1.4 billion\u003c\/strong\u003e people in China, individual consumers have diverse healthcare needs. The growth in health awareness has driven demand for over-the-counter (OTC) medications and health supplements.\u003c\/p\u003e\n\n\u003cp\u003eMayinglong's individual consumer sales account for approximately \u003cstrong\u003e20%\u003c\/strong\u003e of its total revenue, with OTC sales growing by \u003cstrong\u003e15%\u003c\/strong\u003e annually. In 2022, the individual consumer market for health-related products was projected at around \u003cstrong\u003eUSD 45 billion\u003c\/strong\u003e, influenced by trends in self-medication and preventive health measures.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003cthead\u003e\n        \u003ctr\u003e\n            \u003cth\u003eCustomer Segment\u003c\/th\u003e\n            \u003cth\u003eRevenue Contribution (%)\u003c\/th\u003e\n            \u003cth\u003eMarket Size (USD Billions)\u003c\/th\u003e\n            \u003cth\u003eGrowth Rate (%)\u003c\/th\u003e\n        \u003c\/tr\u003e\n    \u003c\/thead\u003e\n    \u003ctbody\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eHospitals and Clinics\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e45%\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e1,050\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e6.5%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eRetail Pharmacies\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e35%\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e58\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eIndividual Consumers\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e20%\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e45\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n        \u003c\/tr\u003e\n    \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis breakdown illustrates how Mayinglong Pharmaceutical Group Co., LTD. strategically focuses on these segments to address varying customer needs while driving revenue and market growth.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMayinglong Pharmaceutical Group Co., LTD. - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eThe cost structure of Mayinglong Pharmaceutical Group Co., LTD. encapsulates various expenditures required to maintain and enhance its operations. The key areas of focus include production costs, research and development (R\u0026amp;D) expenses, and marketing and distribution expenditures.\u003c\/p\u003e\n\n\u003ch3\u003eProduction Costs\u003c\/h3\u003e\n\n\u003cp\u003eProduction costs for Mayinglong are significant, as they include expenses related to raw materials, labor, and manufacturing overhead. In the fiscal year 2022, the company reported total production costs amounting to approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e. The breakdown includes:\u003c\/p\u003e\n\n\u003cul\u003e\n    \u003cli\u003eRaw materials: \u003cstrong\u003eRMB 500 million\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eLabor costs: \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eManufacturing overhead: \u003cstrong\u003eRMB 400 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eR\u0026amp;D Expenses\u003c\/h3\u003e\n\n\u003cp\u003eInvestment in research and development is crucial for Mayinglong to innovate and maintain competitive advantage in the pharmaceutical industry. The company allocated \u003cstrong\u003eRMB 200 million\u003c\/strong\u003e to R\u0026amp;D in 2022, accounting for approximately \u003cstrong\u003e5% of total revenues\u003c\/strong\u003e. This investment has supported several initiatives, including:\u003c\/p\u003e\n\n\u003cul\u003e\n    \u003cli\u003eDevelopment of new formulations: \u003cstrong\u003eRMB 100 million\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eClinical trials and regulatory approvals: \u003cstrong\u003eRMB 70 million\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eCollaborations with academic institutions: \u003cstrong\u003eRMB 30 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eMarketing and Distribution Expenditures\u003c\/h3\u003e\n\n\u003cp\u003eMarketing and distribution costs encompass expenses associated with advertising, sales force, and logistics. Mayinglong reported these costs totaling \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e for 2022. The detailed components include:\u003c\/p\u003e\n\n\u003cul\u003e\n    \u003cli\u003eAdvertising and promotions: \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eSales force compensation: \u003cstrong\u003eRMB 100 million\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eLogistics and distribution: \u003cstrong\u003eRMB 50 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Category\u003c\/th\u003e\n        \u003cth\u003eAmount (RMB)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduction Costs\u003c\/td\u003e\n        \u003ctd\u003e1,200,000,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRaw Materials\u003c\/td\u003e\n        \u003ctd\u003e500,000,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLabor Costs\u003c\/td\u003e\n        \u003ctd\u003e300,000,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Overhead\u003c\/td\u003e\n        \u003ctd\u003e400,000,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n        \u003ctd\u003e200,000,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing and Distribution Expenditures\u003c\/td\u003e\n        \u003ctd\u003e300,000,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThis financial overview emphasizes Mayinglong Pharmaceutical Group’s commitment to balancing effective cost management while investing in critical areas that drive future growth and innovation.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eMayinglong Pharmaceutical Group Co., LTD. - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003ch3\u003eProduct Sales\u003c\/h3\u003e\n\u003cp\u003eMayinglong Pharmaceutical Group generates significant revenue through the sale of pharmaceutical products. In 2022, the company reported revenue from product sales amounting to \u003cstrong\u003eRMB 2.45 billion\u003c\/strong\u003e. This revenue is derived from a diverse portfolio, including over-the-counter medications, prescription drugs, and traditional Chinese medicine.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing Deals\u003c\/h3\u003e\n\u003cp\u003eThe company has established various licensing agreements that contribute to its revenue streams. In 2021, Mayinglong entered into a licensing deal with a European company, which resulted in an additional revenue of \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e. This strategic move allows Mayinglong to leverage its product offerings in international markets while generating royalties from licensing fees.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Grants\u003c\/h3\u003e\n\u003cp\u003eMayinglong Pharmaceutical actively participates in research and development projects funded by government and private entities. In 2022, the company secured \u003cstrong\u003eRMB 150 million\u003c\/strong\u003e in research grants aimed at developing innovative pharmaceutical solutions. This funding supports the advancement of their product pipeline and enhances their competitive position in the market.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eRevenue Source\u003c\/th\u003e\n        \u003cth\u003e2021 Amount (RMB)\u003c\/th\u003e\n        \u003cth\u003e2022 Amount (RMB)\u003c\/th\u003e\n        \u003cth\u003eNotes\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eProduct Sales\u003c\/td\u003e\n        \u003ctd\u003e2.35 billion\u003c\/td\u003e\n        \u003ctd\u003e2.45 billion\u003c\/td\u003e\n        \u003ctd\u003eIncludes OTC and prescription drugs\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLicensing Deals\u003c\/td\u003e\n        \u003ctd\u003e250 million\u003c\/td\u003e\n        \u003ctd\u003e300 million\u003c\/td\u003e\n        \u003ctd\u003eRevenue from international licensing agreements\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eResearch Grants\u003c\/td\u003e\n        \u003ctd\u003e100 million\u003c\/td\u003e\n        \u003ctd\u003e150 million\u003c\/td\u003e\n        \u003ctd\u003eFunds for R\u0026amp;D projects\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45697672904853,"sku":"600993ss-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/600993ss-business-model-canvas.png?v=1739141298","url":"https:\/\/dcf-model.com\/es\/products\/600993ss-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}